Supply of the product Clozapine by Hospira Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves as the foundational piece of legislation governing the regulation of therapeutic goods in Australia. This Act was introduced to address the need for a comprehensive regulatory framework to ensure the safety, quality, and efficacy of therapeutic goods available in the market. One of the key mechanisms under this Act is the ability for the Department of Health, through its delegate, to issue consents for the supply of therapeutic goods that do not fully comply with specific regulatory requirements, provided that such non-compliance does not compromise the safety or quality of the goods. The consent granted for the supply of clozapine tablets by Hospira Australia, despite the label's incorrect sponsor address, exemplifies this mechanism. This consent is subject to conditions that ensure the therapeutic goods meet all other regulatory standards and mitigate any potential risks to public health. The consent issued under section 14 and 14A of the Act for the specific batch of clozapine tablets reflects the policy objective of balancing regulatory compliance with the need to ensure the availability of essential medications. The delegate of the Secretary of the Department of Health has authorised the supply under these specific conditions to prevent any disruption in the provision of a critical therapeutic good while ensuring that other aspects of the product comply with the Therapeutic Goods Order. This approach underscores the Act's aim to maintain public health protection while accommodating reasonable exceptions where appropriate.

Scope and Application

The Therapeutic Goods Act 1989 (the Act) provides a framework for the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood products. Section 14 and 14A of the Act allow the Secretary of the Department of Health to give consent for the supply of therapeutic goods that do not fully comply with certain standards, subject to specific conditions. In this instance, the Secretary's delegate has consented to the supply of clozapine (CLOPINE) tablets 200 mg in a blister pack by Hospira Australia, Melbourne, VIC, for batch 51545, which comprises 2959 packs. This consent specifically addresses non-compliance with the incorrect sponsor address on the label as outlined in paragraph 3(2)(l) of Therapeutic Goods Order (TGO) 69. The consent is strictly limited to this particular batch and non-compliance issue, with all other aspects of the product required to adhere to the Therapeutic Goods Order. The geographic reach of the Act is national, regulating therapeutic goods across Australia, and its application is extended through various subordinate instruments and orders that detail specific compliance requirements.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") includes provisions that govern the supply of therapeutic goods in Australia. Sections 14 and 14A of the Act provide the legal framework for the Therapeutic Goods Administration (TGA) to grant consent for the supply of certain therapeutic goods that do not fully comply with the standards set out in Therapeutic Goods Orders (TGO). In this instance, the delegate of the Secretary of the Department of Health has given consent for the supply of clozapine (CLOPINE) tablets 200 mg in blister packs, specifically batch 51545, which does not conform to the requirements of paragraph 3(2)(l) of TGO 69 due to an incorrect sponsor address on the label. This consent is limited to this particular batch and aspect of non-compliance. The obligations imposed by the Act on the parties involved are quite specific. The Therapeutic Goods Administration, through its delegate, has the authority to grant consent for the supply of goods that do not comply with certain standards, provided that all other aspects of the goods meet the requirements of the relevant Therapeutic Goods Orders. In this case, the Company, Hospira Australia, must ensure that the carton label provided in their application letter is used for the specified batch. Additionally, the Company must ensure that all other aspects of the product comply with the applicable Therapeutic Goods Orders. The consent is strictly limited to the non-compliance with the sponsor address as specified. Failure to adhere to the conditions of the consent, or any other requirements under the Act, may result in serious consequences. While the Act does not explicitly state the penalties for breach, general provisions in the Act allow for significant fines and, in severe cases, criminal charges. For instance, supplying therapeutic goods that do not comply with the standards set by the Therapeutic Goods Orders can attract substantial financial penalties. If the breach is deliberate or involves significant public health risks, it may also lead to criminal charges, with penalties including fines and imprisonment. The exact penalties would depend on the specific breach and the circumstances surrounding it, but they can be severe.